Correlations Between BNP & Dry Weight, and Between Troponin & Mortality, in Hemodialysis Patients
Correlations Between BNP and Dry Weight, and Between Troponin and Mortality, in Hemodialysis Patients
1 other identifier
observational
151
1 country
1
Brief Summary
Beta Natriuretic Peptide (BNP) is regarded as the most sensitive test for congestive heart failure (CHF). BNP has also been found to be highly predictive of other conditions including pulmonary hypertension, pulmonary embolism and in the general population where mild increases are associated with stroke and heart attack. BNP is also weakly and variably correlated with renal function. We believe that each dialysis patient will have an ideal or "dry" BNP level which will accurately and reproducibly reflect their optimal fluid status. Secondary hypotheses are that baseline BNP and troponin, as well as changes in BNP and troponin during dialysis, will be highly predictive of mortality and adequacy of dialysis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2005
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2005
CompletedFirst Submitted
Initial submission to the registry
December 26, 2006
CompletedFirst Posted
Study publicly available on registry
December 27, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2010
CompletedOctober 7, 2010
October 1, 2010
December 26, 2006
October 6, 2010
Conditions
Keywords
Eligibility Criteria
End Stage Renal Disease (ESRD) patients on hemodialysis.
You may qualify if:
- All patients who complete dialysis, are 18 years or older or 85 years or less, and give informed consent will be eligible.
You may not qualify if:
- Inability to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Eastern Virginia Medical Schoollead
- Abbott RDx Cardiometaboliccollaborator
Study Sites (1)
Eastern Virginia Medical School
Norfolk, Virginia, 23508, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mark C Flemmer, MBB Ch
Eastern Virginia Medical School
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 26, 2006
First Posted
December 27, 2006
Study Start
December 1, 2005
Study Completion
December 1, 2010
Last Updated
October 7, 2010
Record last verified: 2010-10